Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEBULA-1 phase 3 study of efimosfermin alfa in compensated cirrhosis due to MASH
CTR20263644Phase 3Active
- Sponsor
- GSK
- Start
- Oct 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of efimosfermin in metabolic dysfunction-associated steatohepatitis (MASH), Cirrhosis, sponsored by GSK. Started Oct 2026; status: active.
02
Drugs
efimosfermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Cirrhosis
Beyond the preview
Go deeper on CTR20263644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263644.